In vivo and in vitro auranofin activity against Trypanosoma cruzi: Possible new uses for an old drug

Experimental Parasitology

Volumn 166, Issue , 2016, Pages 189-193

  da Silva, Marco Túlio Alves ^a   Silva Jardim, Izaltina ^a,c   Portapilla, Gisele Bulhões ^a   de Lima, Gustavo Machado Alvares ^a   Costa, Fernanda Cristina ^a,b,d   Anibal, Fernanda de Freitas ^b   Thiemann, Otavio Henrique ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^c DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

^d BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

Author keywords

Auranofin; Chemotherapy; Trypanosoma cruzi

Indexed keywords

AURANOFIN; BENZNIDAZOLE; ANTIRHEUMATIC AGENT; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

AFRICAN TRYPANOSOMIASIS; ANIMAL EXPERIMENT; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG EFFICACY; EPIMASTIGOTE; IN VITRO STUDY; IN VIVO STUDY; KINETOPLASTIDA; LEISHMANIA; LEISHMANIASIS; MORTALITY; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DRUG EFFECTS; FEMALE; FIBROBLAST; GERMFREE ANIMAL; HUMAN; IC50; LD50; PARASITOLOGY; RANDOMIZATION;

ANIMALS; ANTIRHEUMATIC AGENTS; AURANOFIN; CELL LINE; CHAGAS DISEASE; FEMALE; FIBROBLASTS; HUMANS; INHIBITORY CONCENTRATION 50; LETHAL DOSE 50; MICE; MICE, INBRED BALB C; NITROIMIDAZOLES; PARASITEMIA; RANDOM ALLOCATION; SPECIFIC PATHOGEN-FREE ORGANISMS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84937460155     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2015.05.012     Document Type: Article

References (37)

1. Andrade, R.M., et al. Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. PLoS Negl. Trop. Dis, 8, 2014 e2973.
2. Angelucci, F., et al. Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by Auranofin. J. Biol. Chem 42 (2009), 28977–28985.
3. Brener, Z., Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo 4 (1962), 389–396.
4. Buckner, F.S., et al. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob. Agents Chemother 40 (1996), 2592–2597.
5. Chen, D., et al. Metal complexes, their cellular targets and potential for cancer therapy. Curr. Pharm. Des 15 (2009), 777–791.
6. Cotinguiba, F., et al. Piperamides and their derivatives as potential antitrypanosomal agents. Med. Chem. Res 18 (2009), 703–711.
7. Cox, A.G., et al. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem. Pharmacol 76 (2008), 1097–1109.
8. Díaz-Chiguera, D.L., et al. In vitro and in vivo trypanocidal activity of some benzimidazole derivatives against two strains of Trypanosoma cruzi. Acta Trop 122 (2012), 108–112.
9. Fernandes, J.F., Castellani, J.F., Growth characteristics and chemical composition of Trypanosoma cruzi. Exp. Parasitol 18 (1966), 195–202.
10. Finkelstein, A.E., et al. Auranofin. New oral gold compound for treatment of rheumatoid arthritis. Ann. Rheum. Dis 35 (1976), 251–257.
11. Fricker, S.P., Medical uses of gold compounds: past, present and future. Gold Bull 29 (1996), 56–60.
12. Glennas, A., et al. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br. J. Rheumatol 36 (1997), 870–877.
13. Horton, R.J., Comparative safety and efficacy of auranofin and parenteral gold compounds: a review. Scand. J. Rheumatol. Suppl 51 (1983), 100–110.
14. Hovatta, O., et al. A culture system using human foreskin fibroblasts as feeder cells allows production of human embryonic stem cells. Hum. Reprod 18 (2003), 1404–1409.
15. Ilari, A., et al. A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids 42 (2012), 803–811.
16. Itokazu, M., et al. Efficacy and safety of auranofin in patients with active early rheumatoid arthritis. Clin. Ther 17 (1995), 60–73.
17. Jackson-Rosario, S., Self, W.T., Inhibition of selenium metabolism in the oral pathogen Treponema denticola. J. Bacteriol 12 (2009), 4035–4040.
18. Jackson-Rosario, S., et al. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adduct. J. Biol. Inorg. Chem 14 (2009), 507–519.
19. Kean, W.F., et al. Auranofin. Br. J. Rheumatol. 36 (1997), 560–572.
20. Kuntz, A.N., et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med 4 (2007), 1071–1086.
21. Lobanov, A.V., et al. Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein. Nucleic Acids Res 14 (2006), 4012–4024.
22. Madeira, J.M., et al. The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 20 (2012), 297–306.
23. Martínez-González, J.J., et al. In vitro killing action of auranofin on Taenia crassiceps metacestode (cysticerci) and inactivation of thioredoxin–glutathione reductase (TGR). Parasitol. Res 107 (2010), 227–231.
24. Muelas-Serrano, S., et al. In vitro screening of American plant extracts on Trypanosoma cruzi and Trichomonas vaginalis. J. Ethnopharmacol 71 (2000), 101–107.
25. Navarro, M., Gold complexes as potential anti-parasitic agents. Coord. Chem. Rev 253 (2009), 1619–1626.
26. Parodi-Talice, A., et al. Proteomic analysis of metacyclic trypomastigotes undergoing Trypanosoma cruzi metacyclogenesis. J. Mass Spectrom 42 (2007), 1422–1432.
27. Pizzi, T.P., et al. Acción de la cortisona en la infección experimental por Trypanosoma cruzi. Bol. Chil. Parasitol 7 (1952), 22–24.
28. Romanha, A.J., et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem. Inst. Oswaldo Cruz 105 (2010), 233–238.
29. Sanella, A.R., et al. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett 582 (2008), 844–847.
30. Sannella, A.R., et al. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett 582 (2008), 844–847.
31. Sharlow, E.R., et al. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity. ACS Chem. Biol, 2014, 10.1021/cb400800q.
32. Silva, L.H., Nussenzweig, V., Sobre uma cepa de Trypanosoma cruzi altamente virulenta para camundongo branco. Folia Clin. Biol. 20 (1953), 191–207.
33. Song, L., et al. Thioredoxin glutathione reductase as a novel drug target: evidence from Schistosoma japonicum. PLoS ONE 7 (2012), 1–11.
34. Stoltz, D.R., Bendall, R.D., A simple technique for repeated collection of blood samples from mice. Lab. Anim. Sci 25 (1975), 353–354.
35. Sulsen, V.P., et al. Natural terpenoids from ambrosia species are active in vitro and in vivo against human pathogenic trypanosomatids. PLoS Negl. Trop. Dis 7 (2013), 1–10.
36. Tejman-Yarden, N., et al. A reprofiled drug, auranofin, is effective against metronidazole- resistant Giardia lamblia. Antimicrob. Agents Chemother 57 (2013), 2029–2035.
37. Zingales, B., et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem. Inst. Oswaldo Cruz 104 (2009), 1051–1054.